Information Provided By:
News For THC From the Last 2 Days
THC
May 1, 2024 | 09:50 EDT
Truist analyst David MacDonald raised the firm's price target on Tenet Healthcare to $130 from $120 and keeps a Buy rating on the shares. The firm remains positive on the stock following the company's strong Q1 results, with both revenue and adjusted EBITDA well ahead on solid hospital volumes, brisk revenue per case growth, and robust cost management, the analyst tells investors in a research note.
THC
May 1, 2024 | 09:19 EDT
RBC Capital raised the firm's price target on Tenet Healthcare to $136 from $109 and keeps an Outperform rating on the shares. The firm cites the company's Q1 earnings while also noting its potential for core outperformance this year on strong demand, acuity, and evolving payor mix trends, the analyst tells investors in a research note.
THC
Apr 30, 2024 | 06:47 EDT
Reports Q1 revenue $5.37B vs. $5.02B last year. "We have had an outstanding start to the year highlighted by strong growth in revenues, admissions, and profitability," said Saum Sutaria, M.D., Chairman and Chief Executive Officer of Tenet. "Our operational excellence and focus on continuous improvement helped enable our momentum as we transform our company through strategic portfolio decisions, disciplined capital allocation, and debt reduction."